Effect of Ventilator Hyperinflation Combined With Body Positioning on Arterial Blood Gases In Patients With Ventilator-Associated Pneumonia : A Randomized Controlled Trial

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-60
SponsorAl-Zaytoonah University of Jordan

About this trial

This study aims to evaluate the effect of ventilator hyperinflation combined with body positioning on arterial blood gases in patients with ventilator-associated pneumonia. Forty-two mechanically ventilated patients will be randomly assigned into two groups receiving the intervention in either supine or lateral decubitus positions. Arterial blood gases will be assessed over a 6-day intervention period. The findings are expected to provide evidence regarding the optimal positioning strategy to enhance the effectiveness of ventilator hyperinflation in improving gas exchange in critically ill patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Mechanically ventilated patients ≥ 48 hours

Diagnosed with VAP (clinical + chest X-ray)

Age: 40-60 years

Hemodynamically stable

Disqualifiers

Bilateral lung disease

Unstable cardiovascular conditions

Contraindications to positioning

Re-intubation cases

Trial design

Design model

Parallel

Treatments tested in this trial

  • Ventilator hyperinflation

    Device

    a therapeutic technique used by clinicians (Manual or Ventilator Hyperinflation) to clear secretions and recruit collapsed lung tissue, or an inadvertent complic

  • Manual hyperinflation

    Device

    a respiratory therapy technique that uses a manual resuscitation bag to deliver larger-than-normal, controlled breaths to clear airway secretions and reopen collapsed lung areas

Treatment groups

40 Participants
are divided into 2 treatment groups
Group A: ventilator hyperinflation from lateral decubitus positionExperimental treatment 1 intervention
Group B: Manual hyperinflation for Lateral decubitus positionExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

PaCO2

partial pressure of carbon dioxide in arterial blood, measuring how effectively the lungs eliminate carbon dioxide

Time frame
Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
2

PaO2

partial pressure of oxygen dissolved in arterial blood plasma, measured through an Arterial Blood Gas (ABG) test.

Time frame
Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
3

SaO2

the percentage of oxygen-saturated hemoglobin relative to total hemoglobin in arterial blood, typically measured via an invasive arterial blood gas (ABG) analysis with normal values ranging from 95% to 99%

Time frame
Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
4

PaO2/FiO2 (P/F)

a clinical metric used to evaluate oxygenation efficiency and diagnose the severity of acute hypoxemic respiratory failure or Acute Respiratory Distress Syndrome (ARDS).

Time frame
Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.

Secondary outcomes

1

Pulmonary compliance

the change in lung volume divided by the change in pressure (Δ V / Δ P). Higher compliance means the lungs stretch easily; lower compliance means they are stiff and harder to inflate

Time frame
Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: